Cardiovascular Implications of microRNAs in Coronavirus Disease 2019

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 384; no. 1; pp. 102 - 108
• Main Authors: Izzo, Carmine, Visco, Valeria, Gambardella, Jessica, Ferruzzi, Germano Junior, Rispoli, Antonella, Rusciano, Maria Rosaria, Toni, Anna Laura, Virtuoso, Nicola, Carrizzo, Albino, Di Pietro, Paola, Iaccarino, Guido, Vecchione, Carmine, Ciccarelli, Michele
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2023
• Subjects: Biomarkers - metabolism; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - virology; COVID-19 - complications; Humans; MicroRNAs - metabolism; SARS-CoV-2; COVID-19; ACE2; SARS-CoV-2; CV; IL; miRNA; ICU
• ISSN: 0022-3565; 1521-0103; 1521-0103
• DOI: 10.1124/jpet.122.001210

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or specifically address CV events in COVID-19 patients. The identification of molecular partners contributing to CV manifestations in COVID-19 patients is crucial for providing early biomarkers, prognostic predictors, and new therapeutic targets. The current report will focus on the role of microRNAs (miRNAs) in CV complications associated with COVID-19. Indeed, miRNAs have been proposed as valuable biomarkers and predictors of both cardiac and vascular damage occurring in SARS-CoV-2 infection. It is essential to identify the molecular mediators of coronavirus disease 2019 (COVID-19) cardiovascular (CV) complications. This report focused on the role of microRNAs in CV complications associated with COVID-19, discussing their potential use as biomarkers, prognostic predictors, and therapeutic targets.